AR121843A2 - Formulación oftálmica y método para mejorar la presbicia - Google Patents

Formulación oftálmica y método para mejorar la presbicia

Info

Publication number
AR121843A2
AR121843A2 ARP210100987A ARP210100987A AR121843A2 AR 121843 A2 AR121843 A2 AR 121843A2 AR P210100987 A ARP210100987 A AR P210100987A AR P210100987 A ARP210100987 A AR P210100987A AR 121843 A2 AR121843 A2 AR 121843A2
Authority
AR
Argentina
Prior art keywords
ophthalmic formulation
presbyopia
improve
improve presbyopia
ophthalmic
Prior art date
Application number
ARP210100987A
Other languages
English (en)
Inventor
Restrepo Luis Felipe Vejarano
Original Assignee
Restrepo Luis Felipe Vejarano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Restrepo Luis Felipe Vejarano filed Critical Restrepo Luis Felipe Vejarano
Publication of AR121843A2 publication Critical patent/AR121843A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Formulación oftálmica que comprende una cantidad eficaz de un agente parasimpatomimético que es la pilocarpina o una sal farmacéuticamente aceptable de ésta, así como de uno o más agonistas o antagonistas adrenérgicos a1. La formulación oftálmica puede ser útil para tratar aquellos trastornos que afectan de manera adversa la agudeza visual de un paciente, como es el caso de la presbicia. Método para usar una formulación oftálmica como la que se ha descripto en el tratamiento o la mejora de los síntomas de la presbicia.
ARP210100987A 2012-07-19 2021-04-14 Formulación oftálmica y método para mejorar la presbicia AR121843A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/553,615 US10507245B2 (en) 2012-07-19 2012-07-19 Ophthalmic formulation and method for ameliorating presbyopia

Publications (1)

Publication Number Publication Date
AR121843A2 true AR121843A2 (es) 2022-07-13

Family

ID=48917698

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130102572A AR092860A1 (es) 2012-07-19 2013-07-19 Formulacion oftalmica y metodo para mejorar la presbicia
ARP210100987A AR121843A2 (es) 2012-07-19 2021-04-14 Formulación oftálmica y método para mejorar la presbicia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP130102572A AR092860A1 (es) 2012-07-19 2013-07-19 Formulacion oftalmica y metodo para mejorar la presbicia

Country Status (15)

Country Link
US (2) US10507245B2 (es)
EP (1) EP2874660B1 (es)
CN (2) CN104717981A (es)
AR (2) AR092860A1 (es)
BR (1) BR112015001158B1 (es)
CO (1) CO7250451A2 (es)
DK (1) DK2874660T3 (es)
ES (1) ES2719250T3 (es)
HR (1) HRP20190627T1 (es)
MX (1) MX351230B (es)
PL (1) PL2874660T3 (es)
PT (1) PT2874660T (es)
RU (1) RU2657514C2 (es)
TR (1) TR201905683T4 (es)
WO (1) WO2014015183A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012311239B2 (en) 2011-09-20 2017-10-19 Allergan, Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
EP3104851A1 (en) * 2014-02-11 2016-12-21 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
CN104856990A (zh) * 2015-05-07 2015-08-26 武汉武药科技有限公司 去氧肾上腺素酮咯酸溶液及制备方法
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CH711969A2 (it) * 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
CA3031370A1 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
WO2019150341A1 (en) * 2018-02-05 2019-08-08 Cellixbio Private Limited Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
US20190321334A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US10610518B2 (en) 2018-04-24 2020-04-07 Allergan, Inc. Presbyopia treatments
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
AU2019325486A1 (en) * 2018-08-21 2021-03-25 Allergan, Inc. The use of alpha-2-adrenergic receptor agonists for improving vision
CA3116589A1 (en) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
US11071724B2 (en) * 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
JP2022536662A (ja) * 2019-06-10 2022-08-18 ヴィーサス セラピューティクス インコーポレイテッド 多焦点性を作り出すために偽水晶体患者において副交感神経刺激薬を単独でまたは１種類もしくは複数種類のαアゴニストと組み合わせて使用する方法
MX2020012116A (es) * 2020-11-12 2022-08-09 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia.
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2023125544A1 (zh) * 2021-12-28 2023-07-06 沈阳兴齐眼药股份有限公司 组合物及其在制备用于治疗老花眼的药物中的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DK335086A (da) 1985-08-05 1987-02-06 Michele Testa Kemiske sammensaetninger og farmaceutiske praeparater til topisk brug indeholdende mindst en af de kemiske sammensaetninger i en terapeutiskvirksom maengde
US4902696A (en) * 1987-10-08 1990-02-20 Hoechst-Roussel Pharmaceuticals, Inc. Synergistic intraocular pressure lowering combinations
US5192780A (en) * 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
EP0694310B1 (en) * 1993-04-16 2000-02-16 Wakamoto Pharmaceutical Co., Ltd. Reversible, thermally gelling water-base medicinal composition
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
IT1306135B1 (it) * 1999-04-26 2001-05-30 Farmigea Spa Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto.
US20050261641A1 (en) 2002-09-26 2005-11-24 Warchol Mark P Method for ophthalmic administration of medicament
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
AU2003297511B2 (en) 2002-12-20 2010-01-21 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060166879A1 (en) 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20060172972A1 (en) 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US7252662B2 (en) 2004-11-02 2007-08-07 Lenticular Research Group Llc Apparatus and processes for preventing or delaying one or more symptoms of presbyopia
PT1938839E (pt) 2006-12-18 2009-09-30 Jorge Luis Benozzi Composições oftálmicas de estimulantes parassimpáticos e anti-inflamatórios para utilização no tratamento de presbiopia
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
TNSN08110A1 (en) 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
TWI542338B (zh) 2008-05-07 2016-07-21 壯生和壯生視覺關懷公司 用於活性劑之控制釋放的眼用裝置
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US20120245505A1 (en) 2009-12-16 2012-09-27 Robinson Michael R Intracameral devices for sustained delivery
US20110301555A1 (en) 2010-06-03 2011-12-08 Gonzalez-Zugasti Javier P Porous matrix drug core for lacrimal insert device
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
AU2012311239B2 (en) 2011-09-20 2017-10-19 Allergan, Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism

Also Published As

Publication number Publication date
PT2874660T (pt) 2019-05-14
DK2874660T3 (en) 2019-04-15
CN113425715A (zh) 2021-09-24
AR092860A1 (es) 2015-05-06
ES2719250T3 (es) 2019-07-09
EP2874660B1 (en) 2019-01-23
EP2874660A1 (en) 2015-05-27
BR112015001158B1 (pt) 2020-12-15
RU2015102531A (ru) 2016-09-10
US10507245B2 (en) 2019-12-17
HRP20190627T1 (hr) 2019-06-14
RU2657514C2 (ru) 2018-06-14
TR201905683T4 (tr) 2019-05-21
CO7250451A2 (es) 2015-04-30
MX351230B (es) 2017-10-06
CN104717981A (zh) 2015-06-17
MX2015000806A (es) 2015-08-10
WO2014015183A1 (en) 2014-01-23
PL2874660T3 (pl) 2019-07-31
BR112015001158A2 (pt) 2017-06-27
US20200237916A1 (en) 2020-07-30
US20140024642A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
AR120961A2 (es) Método y composición para tratar hipertensión ocular y glaucoma
CL2017002527A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015).
CL2014000689A1 (es) Composicion para el tratamiento de una condicion ocular que comprende un agonista del receptor de acetilcolina muscarinico m3 y al menos otro agente activo; metodo para tratar presbicia, hipermetropia leve, astigmatismo regular, esotropia acomodativa hipermetropica y glaucoma.
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
TW201613588A (en) Ophthalmic composition
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
AR049929A1 (es) Metodos y composiciones para el tratamiento de afecciones oftalmicas con derivados de retinilo
MY169328A (en) Compositions for the treatment of dry eye
MX2020005217A (es) Composicion oftalmica y dispositivo de administracion de la misma.
MX2011013061A (es) Formulaciones oftalmicas de fluticasona y metodos de uso.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
PE20121520A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular
BR112014014529A2 (pt) métodos para melhorar terapias médicas
EA201390364A1 (ru) Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора pyи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора pyи гиалуроновой кислоты или ее соли
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
AR075413A1 (es) Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
IN2014CN02972A (es)